Navigation Links
Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
Date:4/29/2008

enue rose 43% in the first quarter of 2008 from the same period last year, reflecting demand for our Smartlipo LaserBodySculpting and Affirm Anti-Aging workstations as well as our Elite Aesthetic workstation for hair removal. Average selling prices remained strong and we continued to achieve manufacturing efficiencies. As a result, our first-quarter gross margin improved 430 basis points to a record 66.3% and we more than doubled our net income over the prior-year period."

"We achieved a number of financial milestones in the first quarter of 2008, including our 10th consecutive quarter of revenue growth, our sixth consecutive quarter of profitability and our fifth consecutive quarter of positive cash flow from operations," Davin said. "Even in a challenging macroeconomic environment, we have delivered outstanding results based on our unwavering commitment to having the best technology, products and distribution in the industry. Looking ahead, we believe our customers remain positive about their purchasing intentions and consumer sentiment."

Recent Highlights

-- Cynosure introduced Smartlipo MPX(TM) (MultiPlex), the first

FDA-cleared dual-wavelength system for laser lipolysis. The new

workstation incorporates both a 1064-nm and a 1320-nm wavelength to

remove unwanted pockets of fat and tighten the surrounding tissue with

optimal results. The company plans to introduce Smartlipo MPX in the

United States beginning in the second quarter of 2008 and

internationally in the second half of this year.

-- The company's aesthetic laser technology was featured in five

presentations by some of the industry's leading experts at the 28th

American Society for Laser Medicine and Surgery (ASLMS) Annual

Conference. The data presented at ASLMS provided further support for

the clinical benefits of Cynosure's technology for some of the

aesthetic industry's
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
2. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
3. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
4. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
5. Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... ( http://www.trimarkpublications.com ), a global leader in the biotechnology, ... published Regenerative Medicine Markets report that the ... billion in 2010 and is expected to reach $4.5 ... treat injuries and diseases with specially-grown tissues by way ...
... Sept. 1 UOP LLC, a Honeywell (NYSE: ... was selected for use in Rentech, Inc.,s Rialto Renewable ... fuels. The renewable energy center, to be ... yard and tree trimmings, into renewable, ultra-clean diesel fuel ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... ended September 30, 2010 of approximately $86 million, as ... third quarter of 2009, a 20 percent year-over-year increase. ... 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® for ...
Cached Biology Technology:Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 2Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 2PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 4PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 5
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency ... to detect and prevent counterfeit microcircuits from entering ... agency started performing an in-house microcircuit anti-counterfeit initiative ... authenticity of purchased microcircuits while increasing their reliability ... measures will be conducted at DLA,s Electronics Product ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... in vitro fertilization offers couples the best chance for ... cause doctors to misdiagnose a small fraction of them, ... about the accuracy of preimplantation genetic diagnosis, the method ... IVF, UF researchers set out to study the procedure. ...
... at the University of Rochester Medical Center have discovered a ... harm the function of T-cells, which regulate the body's immune ... adds insight to the latest trend in lead research, as ... to understanding the long-term burden on the body, said Michael ...
... a small vertebra at a construction site near Dallas 17 ... the fossil record. Scientists now know the significance of Turner's ... with an evolutionary twist: a land-dwelling species that became fully ... Dallas Museum of Natural History, but it took several years ...
Cached Biology News:Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3The dangerous legacy of lead 2Missing fossil link 'Dallasaurus' found 2Missing fossil link 'Dallasaurus' found 3Missing fossil link 'Dallasaurus' found 4
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
1 unit is sufficient for 1 caspase activity assay....
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: